Opendata, web and dolomites

NEW DEAL SIGNED

New siRNA Nanotherapy for Inflammatory Bowel Diseases, targeting Janus kinases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NEW DEAL project word cloud

Explore the words cloud of the NEW DEAL project. It provides you a very rough idea of what is the project "NEW DEAL" about.

generate    immunology    selective    plan    immune    safety    innovative    sirna    gi    nanomedicine    immunogenicity    transport    pharma    diseases    therapies    expertise    thanks    historic    rnai    polymeric    mean    proven    carriers    protecting    cells    company    antibodies    lipid    ibd    preclinical    good    jak    clinics    efficacy    young    brings    translation    transfer    combining    validated    locally    avenues    inhibit    inflamed    carefully    gastroenterology    nanosafety    disorders    nanotherapeutics    intestinal    inflammatory    administration    regulatory    solution    drawbacks    transit    submission    therapeutic    manner    safer    tolerability    smes    mediated    oral    jak3    bowel    inhibition    plasma    successful    progress    industrial    nanostructured    mucus    designed    therapy    medicinal    scientists    evaluation    gut    deal    radical    background    capsules    convenience    clinical    people    manufacturing    barrier    biology    tract    patients    experts    stage    membrane   

Project "NEW DEAL" data sheet

The following table provides information about the project.

Coordinator
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES 

Organization address
address: RUE LEBLANC 25
city: PARIS 15
postcode: 75015
website: www.cea.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.newdeal-project.eu
 Total cost 5˙999˙178 €
 EC max contribution 5˙999˙178 € (100%)
 Programme 1. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-NMBP-2016-two-stage
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) coordinator 1˙915˙936.00
2    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) participant 774˙723.00
3    NANOIMMUNOTECH SL ES (VIGO PONTEVEDRA) participant 506˙813.00
4    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 475˙258.00
5    PRODIGEST BE (GENT ZWIJNAARDE) participant 463˙343.00
6    LABORATOIRES MAYOLY SPINDLER FR (CHATOU) participant 448˙750.00
7    HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH DE (BRAUNSCHWEIG) participant 384˙965.00
8    SEPS PHARMA BE (DIEPENBEEK) participant 373˙125.00
9    EUROPEAN RESEARCH SERVICES GMBH DE (MUENSTER) participant 233˙337.00
10    SCIENSEED SL ES (MADRID) participant 190˙288.00
11    ALAN BOYD CONSULTANTS LIMITED UK (CREWE) participant 188˙750.00
12    SPARKS & CO FR (PARIS) participant 43˙886.00

Map

 Project objective

Inflammatory bowel diseases (IBD) are the second most common immune-mediated disorders in Europe, affecting more particularly young people. The current therapies, including antibodies, show three main drawbacks: efficacy, tolerability and convenience. NEW DEAL solution will offer radical therapeutic progress for all IBD patients, thanks to the improved efficacy and increased safety of the specific JAK3 inhibition, which has been proven in clinics to be a target of great interest, the better tolerability of siRNA in term of immunogenicity and the good convenience with oral administration. To achieve this challenge, we will address three objectives: i) Specifically inhibit JAK 3 in a highly selective and safer manner by the mean of siRNA carefully designed and validated, ii) Deliver the siRNA therapeutic locally to the inflamed gut, by combining innovative nanostructured lipid carriers enabling their transport across the mucus, the intestinal barrier and the plasma membrane of the target cells, with polymeric capsules for protecting siRNA nanotherapeutics during their transit along the GI tract, thus allowing an oral administration, and iii) Promote the clinical translation and the future industrial transfer of this new clinical product, by addressing manufacturing, safety and efficacy evaluation at the late preclinical stage, to generate a Regulatory Submission Package and a Clinical Development Plan. The NEW DEAL project brings together clinical experts on IBD, leading scientists in nanomedicine, RNAi biology and immunology, innovative SMEs with a strong background in nanosafety, design of capsules and regulatory issues and an established pharma company with historic expertise on gastroenterology medicinal products. If successful, NEW DEAL will open new avenues for siRNA-based therapy in IBD with oral administration.

 Deliverables

List of deliverables.
Basic communication tools Websites, patent fillings, videos etc. 2019-05-14 12:33:11

Take a look to the deliverables list in detail:  detailed list of NEW DEAL deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Benedikt C. Huck, Olga Hartwig, Alexander Biehl, Konrad Schwarzkopf, Christian Wagner, Brigitta Loretz, Xabier Murgia, Claus-Michael Lehr
Macro- and Microrheological Properties of Mucus Surrogates in Comparison to Native Intestinal and Pulmonary Mucus
published pages: 3504-3512, ISSN: 1525-7797, DOI: 10.1021/acs.biomac.9b00780
Biomacromolecules 20/9 2020-03-05

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEW DEAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEW DEAL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.2.)

nTRACK (2017)

Multimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regeneration

Read More  

ReSiSTant (2018)

Large Riblet Surface with Super Hardnesss, Mechanical and Temperature Resistance by Nano Functionalization

Read More  

iNanoBIT (2017)

Integration of Nano- and Biotechnology for beta-cell and islet Transplantation

Read More